Drug intelligence / Profile preview

Xiltokine

Development stage: Preclinical
Lead developer: Auxi Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

Xiltokine is an autologous cytokine-induced killer (CIK) cell immunotherapy being developed by Auxi Therapeutics. Part of the dendritic cell-cytokine-induced killer (DC-CIK) family of autologous immune cell therapies, Xiltokine consists of ex vivo expanded immune effector cells (primarily CD3+CD56+ NKT cells and CD3+CD56- T cells) that are designed to recognize and destroy tumor cells in a non-major histocompatibility complex (MHC)-restricted manner. Because CIK cells target tumor cells without a specified molecular target, Xiltokine is being developed for a broad range of indications, including hematological malignancies (such as non-Hodgkin lymphoma, diffuse large B-cell lymphoma, multiple myeloma, Hodgkin lymphoma, and acute myeloid leukemia) and various solid tumors (including breast, lung, colorectal, gastric, pancreatic, and liver cancers, among others).

Brand names: Xiltokine

Targets

MICB (Major histocompatibility complex class i-related protein B)MHC I (MHC class I})

Beyond the preview

Go deeper on Xiltokine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiltokine.

Explore the full profile